204 related articles for article (PubMed ID: 31489036)
21. Liposomal irinotecan plus fluorouracil/leucovorin in older patients with advanced pancreatic cancer: a single-center retrospective study.
Nagashima S; Kobayashi S; Tsunoda S; Yamachika Y; Tozuka Y; Fukushima T; Morimoto M; Ueno M; Furuse J; Maeda S
Int J Clin Oncol; 2024 Feb; 29(2):188-194. PubMed ID: 37991558
[TBL] [Abstract][Full Text] [Related]
22. Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial.
Macarulla Mercadé T; Chen LT; Li CP; Siveke JT; Cunningham D; Bodoky G; Blanc JF; Lee KH; Dean A; Belanger B; Wang-Gillam A
Pancreas; 2020 Jan; 49(1):62-75. PubMed ID: 31856081
[TBL] [Abstract][Full Text] [Related]
23. A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid.
Kieler M; Unseld M; Bianconi D; Scheithauer W; Prager GW
Ther Adv Med Oncol; 2019; 11():1758835919853196. PubMed ID: 31360237
[TBL] [Abstract][Full Text] [Related]
24. Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer.
Tang CY; Yang SH; Li CP; Su YY; Chiu SC; Bai LY; Shan YS; Chen LT; Chuang SC; Chan DC; Yen CJ; Peng CM; Chiu TJ; Chen YY; Chen JS; Chiang NJ; Chou WC
Pancreatology; 2024 Jun; 24(4):600-607. PubMed ID: 38565467
[TBL] [Abstract][Full Text] [Related]
25. The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort.
Su YY; Chiang NJ; Tsai HJ; Yen CJ; Shan YS; Chen LT
Sci Rep; 2020 May; 10(1):7420. PubMed ID: 32366911
[TBL] [Abstract][Full Text] [Related]
26. Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer.
Chiang NJ; Chang JY; Shan YS; Chen LT
Expert Opin Pharmacother; 2016 Jul; 17(10):1413-20. PubMed ID: 27140876
[TBL] [Abstract][Full Text] [Related]
27. Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based study.
Chiu TJ; Su YY; Yang SH; Li CP; Bai LY; Chiang NJ; Chuang SC; Shan YS; Chan DC; Chen LT; Yen CJ; Peng CM; Chen YY; Chen JS; Chou WC
Ther Adv Med Oncol; 2021; 13():17588359211058255. PubMed ID: 34819998
[TBL] [Abstract][Full Text] [Related]
28. Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis.
Pelzer U; Blanc JF; Melisi D; Cubillo A; Von Hoff DD; Wang-Gillam A; Chen LT; Siveke JT; Wan Y; Solem CT; Botteman MF; Yang Y; de Jong FA; Hubner RA
Br J Cancer; 2017 May; 116(10):1247-1253. PubMed ID: 28350787
[TBL] [Abstract][Full Text] [Related]
29. Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancer.
Mie T; Sasaki T; Okamoto T; Takeda T; Mori C; Furukawa T; Kasuga A; Matsuyama M; Ozaka M; Sasahira N
Jpn J Clin Oncol; 2022 Dec; 52(12):1399-1407. PubMed ID: 36111430
[TBL] [Abstract][Full Text] [Related]
30. Nanoliposomal Irinotecan With Fluorouracil and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Cholangiocarcinoma: A Phase II Study of the AIO Hepatobiliary-YMO Cancer Groups (NIFE-AIO-YMO HEP-0315).
Ettrich TJ; Modest DP; Sinn M; Striefler JK; Opitz B; Goetze T; Gallmeier E; Angermeier S; Fischer von Weikersthal L; Jacobasch L; Waldschmidt D; Niedermeier M; Sohm M; Berger AW; Manzini G; Fehrenbach U; Auer TA; Hosse C; Vogele D; Sookthai D; Schaaf M; Muche R; Hinke A; Seufferlein T; Perkhofer L
J Clin Oncol; 2024 Jun; ():JCO2301566. PubMed ID: 38843469
[TBL] [Abstract][Full Text] [Related]
31. Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin.
Chiu TJ; Yang SH; Chiu SC; Hsueh SW; Chiang NJ; Li CP; Bai LY; Cheng FM; Chuang SC; Shan YS; Chan DC; Chen LT; Yen CJ; Peng CM; Su YY; Chen YY; Chen JS; Chou WC
J Hepatobiliary Pancreat Sci; 2022 Jun; 29(6):670-681. PubMed ID: 35182031
[TBL] [Abstract][Full Text] [Related]
32. Second-line and third-line therapy with nanoliposomal irinotecan (nal-IRI) in pancreatic cancer: a single-center experience and review of literature.
Möhring C; Frontado Graffe FJ; Bartels A; Sadeghlar F; Zhou T; Mahn R; Marinova M; Feldmann G; Brossart P; Glowka TR; Kalff JC; Strassburg CP; Gonzalez-Carmona MA
J Gastrointest Oncol; 2023 Feb; 14(1):352-365. PubMed ID: 36915455
[TBL] [Abstract][Full Text] [Related]
33. First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer.
Taghizadeh H; Unseld M; Schmiderer A; Djanani A; Wilthoner K; Buchinger D; Prager GW
Cancer Chemother Pharmacol; 2020 Jul; 86(1):109-115. PubMed ID: 32556829
[TBL] [Abstract][Full Text] [Related]
34. Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer.
Chen LT; Macarulla T; Blanc JF; Mirakhur B; Jong FA; Belanger B; Bekaii-Saab T; Siveke JT
Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31357748
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and Safety of the Combination of Nano-Liposomal Irinotecan and 5-Fluorouracil/L-Leucovorin in Unresectable Advanced Pancreatic Cancer: A Real-World Study.
Yasuoka H; Naganuma A; Kurihara E; Kobatake T; Ijima M; Tamura Y; Suzuki Y; Hoshino T; Ishida F; Hosaka H; Hatanaka T; Yoshida S; Aihara R; Hosouchi Y; Ishii N; Araki K; Shirabe K; Uraoka T; Kakizaki S
Oncology; 2022; 100(8):449-459. PubMed ID: 35816996
[TBL] [Abstract][Full Text] [Related]
36. Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan.
Yu KH; Hendifar AE; Alese OB; Draper A; Abdelrahim M; Burns E; Khan G; Cockrum P; Bhak RH; Nguyen C; DerSarkissian M; Duh MS; Bahary N
Front Oncol; 2021; 11():678070. PubMed ID: 34336666
[TBL] [Abstract][Full Text] [Related]
37. Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic Cancer.
Su YY; Chiang NJ; Yang YH; Yen CJ; Bai LY; Chiu CF; Chuang SC; Yang SH; Chou WC; Chen JS; Chiu TJ; Chen YY; Chan DC; Peng CM; Chiu SC; Li CP; Shan YS; Chen LT
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831353
[TBL] [Abstract][Full Text] [Related]
38. FOLFOX regimen after failure of fluorouracil and leucovorin plus nanoliposomal-irinotecan therapy for advanced pancreatic cancer: a retrospective observational study.
Kobayashi S; Tezuka S; Yamachika Y; Tsunoda S; Nagashima S; Tozuka Y; Fukushima T; Morimoto M; Ueno M; Furuse J; Maeda S
BMC Cancer; 2023 Feb; 23(1):177. PubMed ID: 36809997
[TBL] [Abstract][Full Text] [Related]
39. The impact of starting dose with or without subsequent dose escalation of liposomal irinotecan on treatment outcomes in patients with metastatic pancreatic ductal adenocarcinoma.
Chiang NJ; Shan YS; Li CP; Yang SH; Su YY; Chiu SC; Bai LY; Chuang SC; Chan DC; Yen CJ; Peng CM; Chiu TJ; Chen YY; Chen JS; Chou WC
Am J Cancer Res; 2022; 12(11):5062-5073. PubMed ID: 36504882
[TBL] [Abstract][Full Text] [Related]
40. A Retrospective Study Investigating the Safety and Efficacy of Nanoliposomal Irinotecan in Elderly Patients with Unresectable Pancreatic Cancer.
Ikoma T; Matsumoto T; Boku S; Yasuda T; Masuda M; Ito T; Nakamaru K; Yamaki S; Nakayama S; Hashimoto D; Yamamoto T; Shibata N; Ikeura T; Naganuma M; Satoi S; Kurata T
J Clin Med; 2023 May; 12(10):. PubMed ID: 37240585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
